<VariationArchive VariationID="15422" VariationName="NM_000518.5(HBB):c.17_18del (p.Pro6fs)" VariationType="Deletion" Accession="VCV000015422" Version="124" RecordType="classified" NumberOfSubmissions="16" NumberOfSubmitters="16" DateLastUpdated="2024-07-29" DateCreated="2017-09-30" MostRecentSubmission="2024-07-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="30461" VariationID="15422">
      <GeneList>
        <Gene Symbol="HBB" FullName="hemoglobin subunit beta" GeneID="3043" HGNC_ID="HGNC:4827" Source="submitted" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5225464" stop="5227071" display_start="5225464" display_stop="5227071" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5246695" stop="5248300" display_start="5246695" display_stop="5248300" Strand="-" />
          </Location>
          <OMIM>141900</OMIM>
        </Gene>
        <Gene Symbol="LOC106099062" FullName="HBB recombination region" GeneID="106099062" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5226570" stop="5228834" display_start="5226570" display_stop="5228834" Strand="+" />
          </Location>
        </Gene>
        <Gene Symbol="LOC107133510" FullName="origin of replication at HBB" GeneID="107133510" Source="calculated" RelationshipType="within multiple genes by overlap">
          <Location>
            <CytogeneticLocation>11p15.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5222166" stop="5229620" display_start="5222166" display_stop="5229620" Strand="+" />
          </Location>
        </Gene>
      </GeneList>
      <Name>NM_000518.5(HBB):c.17_18del (p.Pro6fs)</Name>
      <CanonicalSPDI>NC_000011.10:5227003:AG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>11p15.4</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="11" Accession="NC_000011.10" start="5227004" stop="5227005" display_start="5227004" display_stop="5227005" variantLength="2" positionVCF="5227003" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="11" Accession="NC_000011.9" start="5248234" stop="5248235" display_start="5248234" display_stop="5248235" variantLength="2" positionVCF="5248233" referenceAlleleVCF="CAG" alternateAlleleVCF="C" />
      </Location>
      <OtherNameList>
        <Name>CD 5 -CT</Name>
      </OtherNameList>
      <ProteinChange>P6fs</ProteinChange>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.10" sequenceAccession="NC_000011" sequenceVersion="10" change="g.5227004_5227005del" Assembly="GRCh38">
            <Expression>NC_000011.10:g.5227004_5227005del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000011.9" sequenceAccession="NC_000011" sequenceVersion="9" change="g.5248234_5248235del" Assembly="GRCh37">
            <Expression>NC_000011.9:g.5248234_5248235del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_000007.3" sequenceAccession="NG_000007" sequenceVersion="3" change="g.70611_70612del">
            <Expression>NG_000007.3:g.70611_70612del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_042296.1" sequenceAccession="NG_042296" sequenceVersion="1" change="g.535_536del">
            <Expression>NG_042296.1:g.535_536del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_046672.1" sequenceAccession="NG_046672" sequenceVersion="1" change="g.4939_4940del">
            <Expression>NG_046672.1:g.4939_4940del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_059281.1" sequenceAccession="NG_059281" sequenceVersion="1" change="g.5067_5068del">
            <Expression>NG_059281.1:g.5067_5068del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000518.5" sequenceAccession="NM_000518" sequenceVersion="5" change="c.17_18del" MANESelect="true">
            <Expression>NM_000518.5:c.17_18del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000509.1" sequenceAccession="NP_000509" sequenceVersion="1" change="p.Pro6fs">
            <Expression>NP_000509.1:p.Pro6fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232" sequenceAccession="LRG_1232">
            <Expression>LRG_1232:g.5067_5068del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="LRG_1232t1" sequenceAccession="LRG_1232t1">
            <Expression>LRG_1232t1:c.17_18del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="LRG_1232p1" sequenceAccession="LRG_1232p1" change="p.Pro6fs">
            <Expression>LRG_1232p1:p.Pro6fs</Expression>
          </ProteinExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef ID="783" DB="HBVAR" />
        <XRef ID="CA125288" DB="ClinGen" />
        <XRef ID="GTR000500319" DB="Genetic Testing Registry (GTR)" />
        <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
        <XRef Type="Allelic variant" ID="141900.0332" DB="OMIM" />
        <XRef Type="rs" ID="34889882" DB="dbSNP" />
      </XRefList>
      <AlleleFrequencyList>
        <AlleleFrequency Value="0.00000" Source="The Genome Aggregation Database (gnomAD)" />
        <AlleleFrequency Value="0.00001" Source="Exome Aggregation Consortium (ExAC)" />
        <AlleleFrequency Value="0.00001" Source="Trans-Omics for Precision Medicine (TOPMed)" />
        <AlleleFrequency Value="0.00004" Source="The Genome Aggregation Database (gnomAD), exomes" />
      </AlleleFrequencyList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND Beta zero thalassemia" Accession="RCV000016678" Version="36">
        <ClassifiedConditionList TraitSetID="4683">
          <ClassifiedCondition DB="MedGen" ID="C0271980">Beta zero thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1989-01-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND not provided" Accession="RCV000506399" Version="45">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="C3661900">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2023-12-30" SubmissionCount="5">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND beta Thalassemia" Accession="RCV000586913" Version="17">
        <ClassifiedConditionList TraitSetID="4697">
          <ClassifiedCondition DB="MedGen" ID="C0005283">beta Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
            <Description DateLastEvaluated="2022-11-03" SubmissionCount="6">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND Hb SS disease" Accession="RCV001004360" Version="9">
        <ClassifiedConditionList TraitSetID="4606">
          <ClassifiedCondition DB="MedGen" ID="C0002895">Hb SS disease</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND multiple conditions" Accession="RCV002476977" Version="8">
        <ClassifiedConditionList TraitSetID="82018">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1858990">Dominant beta-thalassemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C4693822">Erythrocytosis, familial, 6</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002895">Hb SS disease</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0700299">Heinz body anemia</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0019025">Hereditary persistence of fetal hemoglobin</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1840779">METHEMOGLOBINEMIA, BETA TYPE</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C1970028">Malaria, susceptibility to</ClassifiedCondition>
          <ClassifiedCondition DB="MedGen" ID="C0002312">alpha Thalassemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-07-12" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND Beta-thalassemia HBB/LCRB" Accession="RCV004566747" Version="1">
        <ClassifiedConditionList TraitSetID="80504">
          <ClassifiedCondition DB="MedGen" ID="CN322236">Beta-thalassemia HBB/LCRB</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000518.5(HBB):c.17_18del (p.Pro6fs) AND HBB-related disorder" Accession="RCV004541006" Version="1">
        <ClassifiedConditionList TraitSetID="33481">
          <ClassifiedCondition DB="MedGen" ID="CN239378">HBB-related disorder</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2024-02-11" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2024-02-11" NumberOfSubmissions="16" NumberOfSubmitters="16" DateCreated="2017-09-30" MostRecentSubmission="2024-07-15">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15278762</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">17486505</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23457306</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">23637309</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24052702</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25617386</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2606727</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">27263053</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">33491330</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">9225979</ID>
        </Citation>
        <Citation Type="general">
          <URL>https://ithanet.eu/db/ithagenes?ithaID=54</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="4697" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="11970" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Cooley's anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Erythroblastic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Mediterranean anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
                <XRef ID="Beta+Thalassemia/814" DB="Genetic Alliance" />
                <XRef ID="65959000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="871" />
                <XRef ID="871" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="disease mechanism" integerValue="273">loss of function</Attribute>
                <XRef ID="GTR000515560" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520044" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592332" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000567333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000591289" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000522527" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000520115" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000596318" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000260581" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556525" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000529085" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592333" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592286" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501908" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501909" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000508856" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000556526" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000521590" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000558937" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000570317" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000501386" DB="Genetic Testing Registry (GTR)" />
                <XRef ID="GTR000592287" DB="Genetic Testing Registry (GTR)" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-E-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FEA, Hemoglobin E/Beta Plus Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C0005283" DB="MedGen" />
              <XRef ID="MONDO:0019402" DB="MONDO" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4683" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="11956" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta zero thalassemia</ElementValue>
                <XRef ID="86715000" DB="SNOMED CT" />
              </Name>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-EE-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FE, Hemoglobin EE or Hemoglobin E/Beta Zero Thalassemia (Hb EE or Hb E/ß0 Disease), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0271980" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Department Of Translational Genomics (developmental Genetics Section), King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="C3661900" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="33481" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="36575" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">HBB-Related Disorders</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HBB-related condition</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">HBB-related disorder</ElementValue>
              </Name>
              <XRef ID="CN239378" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="80504" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="82018" Type="TraitChoice" ContributesToAggregateClassification="true">
            <Trait ID="40028" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">ERYTHROCYTOSIS, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POLYCYTHEMIA, BETA-GLOBIN TYPE</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Erythrocytosis, familial, 6</ElementValue>
                <XRef ID="MONDO:0054801" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">ECYT6</ElementValue>
                <XRef Type="MIM" ID="617980" DB="OMIM" />
              </Symbol>
              <XRef ID="C4693822" DB="MedGen" />
              <XRef ID="MONDO:0054801" DB="MONDO" />
              <XRef Type="MIM" ID="617980" DB="OMIM" />
            </Trait>
            <Trait ID="16291" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">METHEMOGLOBINEMIA, BETA TYPE</ElementValue>
                <XRef Type="MIM" ID="617971" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0163" DB="OMIM" />
                <XRef Type="Allelic variant" ID="141900.0164" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Methemoglobinemia, beta-globin type</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="13007" />
                <XRef ID="13007" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="C1840779" DB="MedGen" />
              <XRef Type="MIM" ID="617971" DB="OMIM" />
            </Trait>
            <Trait ID="65989" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Beta-thalassemia HBB/LCRB</ElementValue>
                <XRef ID="MONDO:0013517" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Beta-thalassemia (β-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.</Attribute>
                <XRef ID="NBK1426" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301599</ID>
                <ID Source="BookShelf">NBK1426</ID>
              </Citation>
              <XRef ID="CN322236" DB="MedGen" />
              <XRef ID="MONDO:0013517" DB="MONDO" />
              <XRef Type="MIM" ID="613985" DB="OMIM" />
            </Trait>
            <Trait ID="5915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sickle cell anemia</ElementValue>
                <XRef ID="MONDO:0011382" DB="MONDO" />
                <XRef ID="232" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hb SS disease</ElementValue>
                <XRef ID="127040003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickle cell disease</ElementValue>
                <XRef ID="C34383" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HbS disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin S Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickling disorder due to hemoglobin S</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8614" />
                <XRef ID="8614" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.</Attribute>
                <XRef ID="NBK1377" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301551</ID>
                <ID Source="BookShelf">NBK1377</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2009">
                <ID Source="PubMed">19323364</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3111605</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="Yawn et al., 2014">
                <ID Source="PubMed">25203083</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-NBS-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet, [FAS] Sickle Cell Carrier (HbAS)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-S-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb S Screening, 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Carrier Screening ACT Sheet, Sickle Cell Carrier/Trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Disease-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Sickle Cell Disease, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-AS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FAS: Sickle Cell Trait Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="232" DB="Orphanet" />
              <XRef ID="C0002895" DB="MedGen" />
              <XRef ID="MONDO:0011382" DB="MONDO" />
              <XRef Type="MIM" ID="603903" DB="OMIM" />
            </Trait>
            <Trait ID="5228" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Heinz body anemias</ElementValue>
                <XRef ID="Heinz+body+anemias/3265" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Heinz body hemolytic anemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Heinz body anemia</ElementValue>
                <XRef ID="HP:0005511" DB="Human Phenotype Ontology" />
                <XRef ID="MONDO:0007705" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="10718" />
                <XRef ID="10718" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="178330" DB="Orphanet" />
              <XRef ID="C0700299" DB="MedGen" />
              <XRef ID="MONDO:0007705" DB="MONDO" />
              <XRef Type="MIM" ID="140700" DB="OMIM" />
              <XRef Type="primary" ID="HP:0005511" DB="Human Phenotype Ontology" />
            </Trait>
            <Trait ID="55601" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hereditary persistence of fetal hemoglobin</ElementValue>
                <XRef ID="319672" DB="GeneTests" />
                <XRef ID="MONDO:0020989" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">HPFH</ElementValue>
                <XRef Type="MIM" ID="141749" DB="OMIM" />
              </Symbol>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Major-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Hemoglobin F-Only; Hemoglobin F With Decreased A, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Beta-Thalassemia-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin F Only or F with Decreased A: Transfusion Dependent or Non Transfusion Dependent beta-Thalassemia; Hb beta 0 Thalassemia; Hb beta+/beta+ Thalassemia; Hb beta0/beta+ Thalassemia Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="C0019025" DB="MedGen" />
              <XRef ID="MONDO:0020989" DB="MONDO" />
              <XRef Type="MIM" ID="141749" DB="OMIM" />
            </Trait>
            <Trait ID="10300" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Malaria, susceptibility to</ElementValue>
                <XRef ID="MONDO:0021024" DB="MONDO" />
              </Name>
              <XRef ID="673" DB="Orphanet" />
              <XRef ID="C1970028" DB="MedGen" />
              <XRef ID="MONDO:0021024" DB="MONDO" />
              <XRef Type="MIM" ID="611162" DB="OMIM" />
            </Trait>
            <Trait ID="6489" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">A-Thalassemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">alpha Thalassemia</ElementValue>
                <XRef ID="Alpha-Thalassemia/333" DB="Genetic Alliance" />
                <XRef ID="68913001" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha thalassemia spectrum</ElementValue>
                <XRef ID="MONDO:0011399" DB="MONDO" />
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">Alpha-thalassemia (α-thalassemia) has two clinically significant forms: hemoglobin Bart hydrops fetalis (Hb Bart) syndrome (caused by deletion/inactivation of all four α-globin genes; --/--), and hemoglobin H (HbH) disease (most frequently caused by deletion/inactivation of three α-globin genes; --/-α). Hb Bart syndrome, the more severe form, is characterized by prenatal onset of generalized edema and pleural and pericardial effusions as a result of congestive heart failure induced by severe anemia. Extramedullary erythropoiesis, marked hepatosplenomegaly, and a massive placenta are common. Death usually occurs in the neonatal period. HbH disease has a broad phenotypic spectrum: although clinical features usually develop in the first years of life, HbH disease may not present until adulthood or may be diagnosed only during routine hematologic analysis in an asymptomatic individual. The majority of individuals have enlargement of the spleen (and less commonly of the liver), mild jaundice, and sometimes thalassemia-like bone changes. Individuals with HbH disease may develop gallstones and experience acute episodes of hemolysis in response to infections or exposure to oxidant drugs.</Attribute>
                <XRef ID="NBK1435" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="621" />
                <XRef ID="621" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301608</ID>
                <ID Source="BookShelf">NBK1435</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb Screening (non-S), 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, FA + Barts Hb, Alpha (a) Thalassemia, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics Newborn Screening ACT sheet, FA + Barts present (unquantified), FAB, Alpha Thalassemia, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Barts-Present-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Unquantified Barts Alpha Thalassemia Screening Result (FAB), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, Hemoglobin FA + Barts: Low/Moderate Barts Alpha Thalassemia Screening Result (FAB2; FAB1), 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Alpha-Thalassemia-Low-Moderate-Barts-ACT-Sheet.pdf</URL>
                <CitationText>ACMG ACT, FA + Low/Moderate Barts Hb, FAB2, FAB1 Alpha Thalassemia: Silent carrier and alpha thalassemia trait, 2023</CitationText>
              </Citation>
              <XRef ID="846" DB="Orphanet" />
              <XRef ID="C0002312" DB="MedGen" />
              <XRef ID="MONDO:0011399" DB="MONDO" />
              <XRef Type="MIM" ID="604131" DB="OMIM" />
            </Trait>
            <Trait ID="383" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">DYSERYTHROPOIETIC ANEMIA, CONGENITAL, IRISH OR WEATHERALL TYPE</ElementValue>
                <XRef Type="MIM" ID="603902" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Beta-thalassemia, dominant inclusion body type</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Dominant beta-thalassemia</ElementValue>
                <XRef ID="MONDO:0011381" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">D-BTHAL</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17164" />
                <XRef ID="17164" DB="Office of Rare Diseases" />
              </AttributeSet>
              <XRef ID="231226" DB="Orphanet" />
              <XRef ID="848" DB="Orphanet" />
              <XRef ID="C1858990" DB="MedGen" />
              <XRef ID="MONDO:0011381" DB="MONDO" />
              <XRef Type="MIM" ID="603902" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="4606" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5915" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Sickle cell anemia</ElementValue>
                <XRef ID="MONDO:0011382" DB="MONDO" />
                <XRef ID="232" DB="Orphanet" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hb SS disease</ElementValue>
                <XRef ID="127040003" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickle cell disease</ElementValue>
                <XRef ID="C34383" DB="NCI" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HbS disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hemoglobin S Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sickling disorder due to hemoglobin S</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">SCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8614" />
                <XRef ID="8614" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Sickle cell disease (SCD) is characterized by intermittent vaso-occlusive events and chronic hemolytic anemia. Vaso-occlusive events result in tissue ischemia leading to acute and chronic pain as well as organ damage that can affect any organ system, including the bones, spleen, liver, brain, lungs, kidneys, and joints. Dactylitis (pain and/or swelling of the hands or feet) is often the earliest manifestation of SCD. In children, the spleen can become engorged with blood cells in a "splenic sequestration." The spleen is particularly vulnerable to infarction and the majority of individuals with SCD who are not on hydroxyurea or transfusion therapy become functionally asplenic in early childhood, increasing their risk for certain types of bacterial infections, primarily encapsulated organisms. Acute chest syndrome (ACS) is a major cause of mortality in SCD. Chronic hemolysis can result in varying degrees of anemia, jaundice, cholelithiasis, and delayed growth and sexual maturation as well as activating pathways that contribute to the pathophysiology directly. Individuals with the highest rates of hemolysis are at higher risk for pulmonary artery hypertension, priapism, and leg ulcers and may be relatively protected from vaso-occlusive pain.</Attribute>
                <XRef ID="NBK1377" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301551</ID>
                <ID Source="BookShelf">NBK1377</ID>
              </Citation>
              <Citation Type="general" Abbrev="USPSTF, 2009">
                <ID Source="PubMed">19323364</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3111605</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT Sheet, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Anemia-HBss.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Sickle Cell Anemia, 2023</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="Yawn et al., 2014">
                <ID Source="PubMed">25203083</ID>
              </Citation>
              <Citation Type="general" Abbrev="AHA/ASA, 2014">
                <ID Source="PubMed">25355838</ID>
              </Citation>
              <Citation Type="general" Abbrev="EMQN, 2014">
                <ID Source="PubMed">25052315</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-NBS-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet, [FAS] Sickle Cell Carrier (HbAS)</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACOG, 2021">
                <ID Source="PubMed">17197616</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2009">
                <URL>https://www.acmg.net/PDFLibrary/HB-S-Screening-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Hb S Screening, 2009</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Carrier-ACT-Sheet.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Carrier Screening ACT Sheet, Sickle Cell Carrier/Trait, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/Sickle-Cell-Disease-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Sickle Cell Disease, 2012</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-FS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FS: Hemoglobin S Screening Result, 2023</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2023">
                <URL>https://www.acmg.net/PDFLibrary/Hemoglobin-AS-Algorithm.pdf</URL>
                <CitationText>ACMG Algorithm, FAS: Sickle Cell Trait Screening Result, 2023</CitationText>
              </Citation>
              <XRef ID="232" DB="Orphanet" />
              <XRef ID="C0002895" DB="MedGen" />
              <XRef ID="MONDO:0011382" DB="MONDO" />
              <XRef Type="MIM" ID="603903" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1363441" SubmissionDate="2018-01-25" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="NM_000518.4:c.17_18delCT|MedGen:C0005283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000697089" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Women's Health and Genetics/Laboratory Corporation of America, LabCorp" OrgID="500026" OrganizationCategory="laboratory" OrgAbbreviation="WHG-LC" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-06-06">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15278762</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2606727</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17486505</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25617386</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">9225979</ID>
          </Citation>
          <Comment>Variant summary: The HBB c.17_18delCT is a frame-shift variant resulting in termination of translation at codon 23, which is predicted to cause either a truncated or absent HBB protein through non-sense mediated decay which is a commonly known mechanism for BTHAL. Truncations downstream of this position have been classified as pathogenic by our laboratory (e.g. p.Leu29fs). This variant is found in 1/121340 control chromosomes from ExAC at a frequency of 0.0000082, which does not exceed the maximal expected frequency of a pathogenic allele (0.0111803) in this gene. This variant has been commonly identified in beta-thalassemia patients in both compound heterozygous and homozygous states. It is also reported as one of the common mutations in Middle Eastern countries (Lahiry_2008). Taken together, this variant has been classified as a disease variant/pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">LabCorp Variant Classification Summary - May 2015</Attribute>
          <Citation Type="general">
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/rtxspsnt/labcorp_variant_classification_method_-_may_2015.pdf</URL>
            <CitationText>LabCorp Variant Classification Summary - May 2015.docx</CitationText>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <XRefList>
            <XRef DB="dbSNP" ID="34889882" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.17_18delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0005283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2016-2017-variants</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="36948" SubmissionDate="2017-12-12" DateLastUpdated="2018-05-09" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="141900.0332_BETA-ZERO-THALASSEMIA" title="HBB, PRO5FS_BETA-ZERO-THALASSEMIA" />
        <ClinVarAccession Accession="SCV000036948" DateUpdated="2018-05-09" DateCreated="2013-04-04" Type="SCV" Version="2" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1989-01-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Frameshift, -CT, codon 5, CCT to CC, was found in a Mediterranean patient by Kollia et al. (1989).</Attribute>
              <Citation>
                <ID Source="PubMed">2606727</ID>
              </Citation>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <Name>HBB, PRO5FS</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">PRO5FS</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="141900.0332" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">BETA-ZERO-THALASSEMIA</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1550127" SubmissionDate="2018-07-10" DateLastUpdated="2018-03-17" DateCreated="2018-03-17">
        <ClinVarSubmissionID localKey="23265|OMIM:613985" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000799824" DateUpdated="2018-03-17" DateCreated="2018-03-17" Type="SCV" Version="1" SubmitterName="Counsyl" OrgID="320494" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-05-08">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">24052702</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">15278762</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25617386</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2606727</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Counsyl Autosomal Recessive and X-Linked Classification Criteria (2018)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/sbjulxjt/counsyl_autosomal_recessive_and_x-linked_classification_criteria_2018_.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="C" referenceAllele="CAG" start="5248233" stop="5248235" variantLength="3" />
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.17_18delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB4282047</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2292354" SubmissionDate="2019-09-27" DateLastUpdated="2020-02-29" DateCreated="2020-02-29">
        <ClinVarSubmissionID localKey="NC_000011.9:g.5248234_5248235delAG|OMIM:603903" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001163298" DateUpdated="2020-02-29" DateCreated="2020-02-29" Type="SCV" Version="1" SubmitterName="Baylor Genetics" OrgID="1006" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification>
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5248234_5248235delAG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603903" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>BG_GA_2018_SNVs_INDELS</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2454112" SubmissionDate="2019-11-25" DateLastUpdated="2020-05-04" DateCreated="2020-05-04">
        <ClinVarSubmissionID localKey="ithaID:54|Orphanet:ORPHA:848" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV001244626" DateUpdated="2020-05-04" DateCreated="2020-05-04" Type="SCV" Version="1" SubmitterName="The ITHANET community portal, The Cyprus Institute of Neurology and Genetics" OrgID="507248" OrganizationCategory="locus-specific database (LSDB)" OrgAbbreviation="ITHANET" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-11-25">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">2606727</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27263053</ID>
          </Citation>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>CD 5 -CT</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="dbSNP" ID="34889882" Type="rsNumber" />
          </XRefList>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">beta Thalassemia</ElementValue>
            </Name>
            <XRef DB="Orphanet" ID="ORPHA848" />
          </Trait>
        </TraitSet>
        <Citation>
          <URL>https://ithanet.eu/db/ithagenes?ithaID=54</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB6599191</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4086632" SubmissionDate="2022-02-09" DateLastUpdated="2022-04-23" DateCreated="2022-04-23">
        <ClinVarSubmissionID localKey="NM_000518.5:c.17_18del|Beta thalassemia" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002091615" DateUpdated="2022-04-23" DateCreated="2022-04-23" Type="SCV" Version="1" SubmitterName="Natera, Inc." OrgID="500034" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2017-03-17">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Beta thalassemia</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10993736</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3448298" SubmissionDate="2022-12-13" DateLastUpdated="2022-12-31" DateCreated="2021-07-18">
        <ClinVarSubmissionID localKey="NM_000518.5:c.17_18del|OMIM:140700;141749;603902;603903;604131;611162;613985;617971;617980" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001752822" DateUpdated="2022-12-31" DateCreated="2021-07-18" Type="SCV" Version="2" SubmitterName="Fulgent Genetics, Fulgent Genetics" OrgID="500105" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-12">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="TraitChoice">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="140700" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="141749" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603902" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="603903" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="604131" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="611162" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617971" Type="MIM" />
          </Trait>
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="617980" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB12390657</SubmissionName>
          <SubmissionName>SUB9977930</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="1164947" SubmissionDate="2023-12-22" DateLastUpdated="2024-01-06" DateCreated="2017-09-30">
        <ClinVarSubmissionID localKey="S6844|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000601252" DateUpdated="2024-01-06" DateCreated="2017-09-30" Type="SCV" Version="3" SubmitterName="Quest Diagnostics Nichols Institute San Juan Capistrano" OrgID="500110" OrganizationCategory="laboratory" OrgAbbreviation="Quest Diagnostics" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">33491330</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">25617386</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2606727</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">27263053</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">23457306</ID>
          </Citation>
          <Comment>The HBB c.17_18del (p.Pro6Argfs*17) variant (also known as CD5 (-CT)) alters the translational reading frame of the HBB mRNA and causes the premature termination of HBB protein synthesis. In the published literature, this variant has been reported in the compound heterozygous and homozygous state in individuals with beta-thalassemia major and intermedia (PMIDs: 33491330 (2021), 27263053 (2016), 25617386 (2015), 2606727 (1989)). Based on the available information, this variant is classified as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Quest Diagnostics criteria</Attribute>
          <Citation>
            <ID Source="PubMed">26467025</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14108248</SubmissionName>
          <SubmissionName>SUB2915479</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2284666" SubmissionDate="2024-01-24" DateLastUpdated="2024-02-20" DateCreated="2020-02-10">
        <ClinVarSubmissionID localKey="3420723|MedGen:CN235283" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001160085" DateUpdated="2024-02-20" DateCreated="2020-02-10" Type="SCV" Version="8" SubmitterName="ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories" OrgID="25969" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-11-15">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBB c.17_18delCT; p.Pro6ArgfsTer17 variant (rs34889882, HbVarID: 783), also known as Codon 5 (-CT) or Pro5fs when numbered from the mature protein, has been reported in the literature in an individual with beta(0) thalassemia (Kollia 1989, HbVar database and references therein). This variant is reported as pathogenic in ClinVar (Variation ID: 15422). It is found in the general population with an overall allele frequency of 0.004% (11/251156 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting 2 nucleotides, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: Link to HbVar database: https://globin.bx.psu.edu/hbvar/menu.html Kollia et al. Frameshift codon 5 (Fsc-5 (-CT)) thalassemia; a novel mutation detected in a Greek patient. Hemoglobin. 1989;13(6):597-604. PMID: 2606727.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ARUP Molecular Germline Variant Investigation Process 2024</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/xwiqgyug/arup_molecular_germline_variant_investigation_process_arup-info-0022_2024.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5248234_5248235del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN235283" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2020 ARUP</SubmissionName>
          <SubmissionName>2022 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>2023 ARUP ClinVar submission</SubmissionName>
          <SubmissionName>ARUP Molecular 2021</SubmissionName>
          <SubmissionName>May 2022</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="8876733" SubmissionDate="2024-03-08" DateLastUpdated="2024-03-16" DateCreated="2024-03-16">
        <ClinVarSubmissionID localKey="5957949|HBB-related condition" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV004793003" DateUpdated="2024-03-16" DateCreated="2024-03-16" Type="SCV" Version="1" SubmitterName="PreventionGenetics, part of Exact Sciences" OrgID="239772" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-11">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The HBB c.17_18delCT variant is predicted to result in a frameshift and premature protein termination (p.Pro6Argfs*17). This variant is also known as Codon 5 [-CT], FSC-5(-CT), or CD 5 -CT in the literature. This variant was reported in the homozygous and compound heterozygous states to be causative for autosomal recessive beta-thalassemia (Kollia et al. 1989. PubMed ID: 2606727; Elmezayen et al. 2015. PubMed ID: 25617386; Murad et al. 2021. PubMed ID: 33491330). This variant is reported in 0.036% of alleles in individuals of South Asian descent in gnomAD. Frameshift variants in HBB are expected to be pathogenic. This variant is interpreted as pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.4:c.17_18delCT</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">HBB-related condition</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14299258</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9056889" SubmissionDate="2024-04-19" DateLastUpdated="2024-04-20" DateCreated="2024-04-20">
        <ClinVarSubmissionID localKey="50564723|Orphanet:ORPHA848" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004847531" DateUpdated="2024-04-20" DateCreated="2024-04-20" Type="SCV" Version="1" SubmitterName="Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine" OrgID="21766" OrganizationCategory="laboratory" OrgAbbreviation="LMM" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2022-11-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>The p.Pro6ArgfsX17 variant in HBB has been reported in several individuals with beta thalassemia and is one of the common pathogenic variants in Middle Eastern countries ( selected references Kollia 1989 PMID: 2606727, Vetter 1997 PMID: 9163586, Murad 2021 PMID: 33491330). It has also been reported in ClinVar (Variation ID 15422) and was identified in 6/4834 South Asian chromosomes by gnomAD (https://gnomad.broadinstitute.org). This variant is predicted to cause a frameshift, which alters the protein’s amino acid sequence beginning at position 6 and leads to a premature termination codon 17 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. Loss of function of the HBB gene is an established disease mechanism in autosomal recessive beta thalassemia. In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive beta thalassemia. ACMG/AMP Criteria applied: PM2_Supporting, PVS1, PM3_Strong.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <GeneLocation>NM_000518.5:exon 1</GeneLocation>
          </Location>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.10:g.5227004_5227005delAG</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="Orphanet" ID="ORPHA848" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14389831</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2863034" SubmissionDate="2020-11-26" DateLastUpdated="2020-12-12" DateCreated="2020-12-12">
        <ClinVarSubmissionID localKey="NM_000518.5:c.17_18del|not provided" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001450168" DateUpdated="2020-12-12" DateCreated="2020-12-12" Type="SCV" Version="1" SubmitterName="Clinical Genetics and Genomics, Karolinska University Hospital" OrgID="505315" OrganizationCategory="laboratory" OrgAbbreviation="KLINGEN-KUS" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2016-01-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="7" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB8639822</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3551546" SubmissionDate="2021-08-30" DateLastUpdated="2021-09-08" DateCreated="2021-09-08">
        <ClinVarSubmissionID localKey="NM_000518.5:c.17_18del|OMIM:613985" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001810474" DateUpdated="2021-09-08" DateCreated="2021-09-08" Type="SCV" Version="1" SubmitterName="Genome-Nilou Lab" OrgID="507598" OrganizationCategory="laboratory" OrgAbbreviation="Genome Nilou" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-07-22">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10282909</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2381150" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-14" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="4890645|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001215748" DateUpdated="2024-02-14" DateCreated="2020-04-15" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-12-30">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">23637309</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2606727</ID>
          </Citation>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro6Argfs*17) in the HBB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in HBB are known to be pathogenic (PMID: 23637309). This variant is present in population databases (rs34889882, gnomAD 0.04%). This premature translational stop signal has been observed in individual(s) with beta thalassemia (PMID: 2606727). This variant is also known as Pro5fs and FSC-5(-CT). ClinVar contains an entry for this variant (Variation ID: 15422). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000011.9:g.5248234_5248235del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12508014</SubmissionName>
          <SubmissionName>SUB14200283</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="9810857" SubmissionDate="2024-06-11" DateLastUpdated="2024-06-17" DateCreated="2024-06-17">
        <ClinVarSubmissionID localKey="NM_000518.5:c.17_18del|OMIM:613985" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV005051815" DateUpdated="2024-06-17" DateCreated="2024-06-17" Type="SCV" Version="1" SubmitterName="Laboratory of Medical Genetics, National &amp; Kapodistrian University of Athens" OrgID="506664" OrganizationCategory="laboratory" OrgAbbreviation="LMG-NKUA" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2024-02-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ACMG Guidelines, 2015</Attribute>
          <Citation>
            <ID Source="PubMed">25741868</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>no</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NM_000518.5:c.17_18del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613985" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB14526024</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="2957532" SubmissionDate="2024-07-04" DateLastUpdated="2024-07-15" DateCreated="2021-03-14">
        <ClinVarSubmissionID localKey="106026|MedGen:CN517202" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001500949" DateUpdated="2024-07-15" DateCreated="2021-03-14" Type="SCV" Version="20" SubmitterName="CeGaT Center for Human Genetics Tuebingen" OrgID="505870" OrganizationCategory="laboratory" OrgAbbreviation="CHGT" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-08-01">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/0ynenhfo/cegat_center_for_human_genetics_tuebingen_-_variant_classification_criteria_-_version_2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>yes</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="HBB" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="11" alternateAllele="C" referenceAllele="CAG" start="5248233" stop="5248235" variantLength="3" />
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="CN517202" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>2021-07</SubmissionName>
          <SubmissionName>2021-10</SubmissionName>
          <SubmissionName>2022-01</SubmissionName>
          <SubmissionName>2022-01-corrected</SubmissionName>
          <SubmissionName>2022-04</SubmissionName>
          <SubmissionName>2022-07</SubmissionName>
          <SubmissionName>2022-08</SubmissionName>
          <SubmissionName>2022-10.3</SubmissionName>
          <SubmissionName>2023-01</SubmissionName>
          <SubmissionName>2023-04</SubmissionName>
          <SubmissionName>2023-09-add-ACMG-details</SubmissionName>
          <SubmissionName>2023-10</SubmissionName>
          <SubmissionName>2024-04</SubmissionName>
          <SubmissionName>SUB13641132</SubmissionName>
          <SubmissionName>SUB13985080</SubmissionName>
          <SubmissionName>SUB14102099</SubmissionName>
          <SubmissionName>SUB14290090</SubmissionName>
          <SubmissionName>SUB14426581</SubmissionName>
          <SubmissionName>SUB14513473</SubmissionName>
          <SubmissionName>SUB14584463</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1550127" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="603903" MappingRef="OMIM">
        <MedGen CUI="C0002895" Name="Hb SS disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="4086632" TraitType="Disease" MappingType="Name" MappingValue="Beta thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2284666" TraitType="Disease" MappingType="XRef" MappingValue="CN235283" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2381150" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="617971" MappingRef="OMIM">
        <MedGen CUI="C1840779" Name="METHEMOGLOBINEMIA, BETA TYPE" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2863034" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9810857" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="603902" MappingRef="OMIM">
        <MedGen CUI="C1858990" Name="Dominant beta-thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1164947" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2454112" TraitType="Disease" MappingType="Name" MappingValue="beta Thalassemia" MappingRef="Preferred">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="611162" MappingRef="OMIM">
        <MedGen CUI="C1970028" Name="Malaria, susceptibility to" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1363441" TraitType="Disease" MappingType="XRef" MappingValue="C0005283" MappingRef="MedGen">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="9056889" TraitType="Disease" MappingType="XRef" MappingValue="ORPHA848" MappingRef="Orphanet">
        <MedGen CUI="C0005283" Name="beta Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2957532" TraitType="Disease" MappingType="XRef" MappingValue="CN517202" MappingRef="MedGen">
        <MedGen CUI="C3661900" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="141749" MappingRef="OMIM">
        <MedGen CUI="C0019025" Name="Hereditary persistence of fetal hemoglobin" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="604131" MappingRef="OMIM">
        <MedGen CUI="C0002312" Name="alpha Thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="36948" TraitType="Disease" MappingType="Name" MappingValue="BETA-ZERO-THALASSEMIA" MappingRef="Preferred">
        <MedGen CUI="C0271980" Name="Beta zero thalassemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="2292354" TraitType="Disease" MappingType="XRef" MappingValue="603903" MappingRef="OMIM">
        <MedGen CUI="C0002895" Name="Hb SS disease" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="140700" MappingRef="OMIM">
        <MedGen CUI="C0700299" Name="Heinz body anemia" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="8876733" TraitType="Disease" MappingType="Name" MappingValue="HBB-related condition" MappingRef="Preferred">
        <MedGen CUI="CN239378" Name="HBB-related disorder" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3551546" TraitType="Disease" MappingType="XRef" MappingValue="613985" MappingRef="OMIM">
        <MedGen CUI="CN322236" Name="Beta-thalassemia HBB/LCRB" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3448298" TraitType="Disease" MappingType="XRef" MappingValue="617980" MappingRef="OMIM">
        <MedGen CUI="C4693822" Name="Erythrocytosis, familial, 6" />
      </TraitMapping>
    </TraitMappingList>
    <DeletedSCVList>
      <SCV>
        <Accession Version="1" DateDeleted="2023-03-03">SCV002024967</Accession>
        <Description>not specified</Description>
      </SCV>
    </DeletedSCVList>
  </ClassifiedRecord>
</VariationArchive>

